Static analysis to make the most of CHERI C/C plus plus for existing code: improving memory safety at scale

被引:0
|
作者
Dudina, Irina [1 ]
Stark, Ian [1 ]
机构
[1] Univ Edinburgh, Edinburgh, Scotland
关键词
Static analysis; CHERI; Software porting;
D O I
10.1007/s10009-025-00781-6
中图分类号
TP31 [计算机软件];
学科分类号
081202 ; 0835 ;
摘要
We describe and evaluate custom static analyses to support transitioning existing C/C++ codebases to CHERI hardware. CHERI is a novel architectural extension, implemented for RISC-V and AArch64, that uses capabilities to provide fine-grained memory protection and scalable software compartmentalization. While the existing CHERI toolchain can recompile large code collections for the platform with only a few source changes, those changes are nonetheless critical: we demonstrate that static analysis can help to identify where they are needed and what must be done to avoid later runtime faults. We provide custom checkers for the Clang Static Analyzer to handle capability alignment, copying through memory, and manipulation as integers. Beyond simply picking up problems in existing code, we also have checkers that identify where code can take advantage of capabilities to better enforce least privilege and improve spatial memory safety. We evaluate all implemented checkers on a sample of packages from the CheriBSD ports library (408 packages, analyzed) and confirm by analyzing true-positive warning rates that the reports produced are sufficiently high quality for practical use.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Safety and efficacy of PEG IFN alfa-2b plus ribavirin for recurrent hepatitis C after liver transplantation: A preliminary analysis.
    Ghalib, RH
    Levine, CD
    Hollinger, B
    Stribling, R
    McClelland, T
    Box, TD
    Hutson, WR
    Post, AB
    Regenstein, FG
    Goshi, S
    Weinstein, J
    Seu, P
    Goss, J
    Cheng, S
    HEPATOLOGY, 2003, 38 (04) : 528A - 528A
  • [42] Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E plus C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis
    Tabernero, J.
    Van Cutsem, E.
    Yoshino, T.
    Yaeger, R.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Alkuzweny, B.
    Zhang, X.
    Guenzil, C.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S174 - S174
  • [43] PRELIMINARY SAFETY ANALYSIS FROM PAC-C STUDY OF CAPECITABINE plus PACLITAXEL→CAPECITABINE MAINTENANCE (PX-X) VS CAPECITABINE plus CISPLATIN (XP) AS FIRST-LINE CHEMOTHERAPY FOR RECURRENT/METASTATIC GASTRIC CANCER
    Shen, Lin
    Zhang, Xiaotian
    Lu, Zhihao
    Hu, Bing
    Fan, Qingxia
    Li, Wei
    Liu, Wei
    Liu, Tianshu
    Pan, Yueyin
    Xu, Nong
    ANNALS OF ONCOLOGY, 2012, 23 : 43 - 44
  • [44] Tonsillectomy plus steroid pulse therapy is the most effective treatment in adult patients with C-Grade I IgA nephropathy, and the weight of the extracted palatine tonsils and Yamamoto scale have no significant correlation with the effects of this treatment
    Kondo, Norio
    Moriyama, Takahito
    Tachikawa, Mayako
    Tomita, Erika
    Hattori, Ai
    Yamamura, Yukie
    Nonaka, Manabu
    AURIS NASUS LARYNX, 2019, 46 (05) : 764 - 771
  • [45] Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
    Schadendorf, Dirk
    Gogas, Helen
    Sekulovic, Lidija Kandolf
    Meier, Friedegund Elke
    Eigentler, Thomas
    Simon, Jan-Christoph
    Terheyden, Patrick Andres Maximilian
    Gesierich, Anja Heike
    Herbst, Rudolf Alexander
    Kahler, Katharina C.
    Ziogas, Dimitrios C.
    Mijuskovic, Zeljko
    Garzarolli, Marlene
    Garbe, Claus
    Roesch, Alexander
    Ugurel, Selma
    Gutzmer, Ralf
    Grob, Jean-Jacques
    Zimmer, Lisa
    Livingstone, Elisabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Efficacy and Safety of Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta-analysis
    Druyts, Eric
    Thorlund, Kristian
    Wu, Ping
    Kanters, Steve
    Yaya, Sanni
    Cooper, Curtis L.
    Mills, Edward J.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (07) : 961 - 967
  • [47] Meta-analysis of Efficacy and Safety Outcomes Associated With the Basal-Plus Regimen of Insulin Glargine and Insulin Glulisine among Type 2 Diabetes Patients With HbA1c≥8%
    Raccah, Denis
    Lin, Jay
    Bahloul, Amar
    Wang, Edward
    Penfornis, Alfred
    DIABETES, 2012, 61 : A620 - A620
  • [48] Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin Protocol for a systemic review and meta-analysis
    Yao, Jia-Chen
    Cui, Min
    Pan, Mang-Mang
    Gu, Zhi-Chun
    Li, Wen-Yan
    MEDICINE, 2018, 97 (24)
  • [49] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chen, Chun-Hsien
    Chen, Chien-Hung
    Lin, Chih-Lang
    Lin, Chun-Yen
    Hu, Tsung-Hui
    Tung, Shui-Yi
    Hsieh, Sen-Yung
    Lu, Sheng-Nan
    Chien, Rong-Nan
    Hung, Chao-Hung
    Sheen, I-Shyan
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [50] Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
    Manns, Michael P.
    McCone, Jonathan, Jr.
    Davis, Mitchell N.
    Rossaro, Lorenzo
    Schiff, Eugene
    Shiffman, Mitchel L.
    Bacon, Bruce
    Bourliere, Marc
    Sulkowski, Mark S.
    Bruno, Savino
    Balart, Luis
    Bronowicki, Jean-Pierre
    Kwo, Paul
    Poordad, Fred
    Felizarta, Franco
    Reddy, K. Rajender
    Helmond, Frans A.
    Sings, Heather L.
    Pedicone, Lisa D.
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Vierling, John M.
    LIVER INTERNATIONAL, 2014, 34 (05) : 707 - 719